Compare GWAV & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GWAV | KALA |
|---|---|---|
| Founded | 2002 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 3.4M |
| IPO Year | 2014 | 2017 |
| Metric | GWAV | KALA |
|---|---|---|
| Price | $2.13 | $0.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.4K | ★ 283.3K |
| Earning Date | 08-18-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,098,036.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 116184.26 | N/A |
| 52 Week Low | $1.91 | $0.07 |
| 52 Week High | $8.50 | $191.00 |
| Indicator | GWAV | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 38.87 | 31.06 |
| Support Level | $1.91 | $0.11 |
| Resistance Level | $4.12 | $0.35 |
| Average True Range (ATR) | 0.21 | 0.03 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 11.78 | 10.14 |
Greenwave Technology Solutions Inc through its subsidiary, is an operator of several metal recycling facilities in Virginia, Ohio, & North Carolina. At these facilities, the company collects, classifies, & processes appliances, construction materials, end-of-life vehicles, boats, & industrial machinery. The company processes these items by crushing, shearing, shredding, separating, & sorting into smaller pieces & categorizes these recycled ferrous, nonferrous, & mixed metal pieces based on density & metal type before sale. For scrap cars, it removes the catalytic converters, aluminum wheels, & batteries for separate processing & sale before shredding the vehicle. The company is organized into three operating segments: Scrap Metal Recycling, Hauling, & Other (comprised of rental income).
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.